| 2001.04 |
- |
Founded in Minato-ku, Tokyo to contribute in research and development of anti-cancer medicine, cancer therapy and cancer diagnosis based on oncogenes and proteins
|
| 2001.05 |
- |
Commenced a collaboration with the Institute of Medical Science, the University of Tokyo |
| 2001.11 |
- |
Head office was moved to Shirokanedai, Minato-ku, Tokyo |
| 2002.06 |
- |
Tied up with the Medical & Biological Laboratories Co., Ltd. (MBL) in research and development of diagnosis and research reagents for cancer utilizing oncogene information |
| 2002.07 |
- |
Contracted with Banyu Pharmaceutical Co., Ltd to create an assay system to screen drugs for anti-hepatocellular carcinoma |
| 2002.08 |
- |
Tied up with Shionogi Co., Ltd in research and development of drugs for lung cancer, prostate cancer and breast cancer utilizing oncogene information |
| 2002.10 |
- |
Opened laboratory at the same place as head office |
| 2003.09 |
- |
Tied up with Sankyo Co., Ltd. in research and development of antibody medicines for lung cancer |
| 2003.09 |
- |
Set up a consortium with MBL and its subsidiary company, Institute for Antibodies CO., LTD. (IFA), to develop antibody-based medicines by taking advantage of expertise of each company, such as oncogene information (OTS) and technology to generate specific antibodies (MBL and IFA) |
| 2003.10 |
- |
Tied up with Otsuka Pharmaceutical Co., Ltd. in research and development of vaccines for colon cancer |
| 2003.11 |
- |
Concluded the agreement to provide Palma Bee'Z Research Institute Co., Ltd., Sanko Junyaku Co., Ltd., and Eisai Co., Ltd. with information on lung oncogenes for diagnosis development |
| 2003.12 |
- |
Listed on Mothers market of the Tokyo Securities Exchange |
| 2004.03 |
- |
Concluded the agreement with Yakult Honsha Co., Ltd. on research and development of antibody medicines for lung cancer |
| 2004.06 |
- |
Concluded the agreement with KUREHA CORPORATION on research and development of antibody medicines for pancreas cancer |
| 2004.08 |
- |
Jointly established OMAb Pharma, Inc. (Immunas Pharma, Inc. at present)with MBL, to develop and commercialize antibody medicines |
| 2005.03 |
- |
Head office and Laboratory facility were moved to Takatsu-ku, Kawasaki city, Kanagawa prefecture, and opened Drug Discovery Laboratory at the same address
|
| 2005.04 |
- |
Concluded the agreement to provide Fuso Pharmaceutical Industries, Ltd. with license of sales of the angiogenesis inhibitor, OTS102, in Japan |
| 2006.03 |
- |
Submitted an application of Investigational new drug (IND) of the angiogenesis inhibitor, OTS102, for Phase I trial |
